¼¼°èÀÇ ´º·ÎÅ×Å© µð¹ÙÀ̽º ½ÃÀå
Neurotech Devices
»óǰÄÚµå : 1782950
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 296 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

´º·ÎÅ×Å© µð¹ÙÀ̽º ¼¼°è ½ÃÀåÀº 2030³â±îÁö 303¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 152¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ´º·ÎÅ×Å© µð¹ÙÀ̽º ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 12.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 303¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½Å°æ ÀÚ±ØÀº CAGR 10.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 124¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Å°æ Àΰø±â°ü(Neuroprostheses) ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR·Î 14.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 41¾ï ´Þ·¯, Áß±¹Àº CAGR 16.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´º·ÎÅ×Å© µð¹ÙÀ̽º ½ÃÀåÀº 2024³â¿¡ 41¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 63¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 16.1%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 9.1%¿Í 10.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ´º·ÎÅ×Å© µð¹ÙÀ̽º ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

´º·ÎÅ×Å© µð¹ÙÀ̽º´Â ³ú-ÄÄÇ»ÅÍ »óÈ£ÀÛ¿ë°ú ½Å°æ °Ç°­¿¡ ¾î¶² Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖÀ»±î?

´º·ÎÅ×Å© µð¹ÙÀ̽º´Â ³ú-ÄÄÇ»ÅÍ ÀÎÅÍÆäÀ̽º(BCI), ½Å°æÀÚ±ØÄ¡·á, ÀÎÁö±â´É °­È­, ½Ç½Ã°£ ½Å°æ ¸ð´ÏÅ͸µ µîÀ» ÅëÇØ Àΰ£°ú ±â¼úÀÇ °ü°è¸¦ º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ ÀåÄ¡µéÀº ½Å°æ°úÇаú µðÁöÅÐ ±â¼úÀ» ¿¬°áÇÏ¿© °£Áú, ¿ì¿ïÁõ, ÆÄŲ½¼º´, ô¼ö¼Õ»ó µîÀÇ Áõ»ó¿¡ ȹ±âÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ³ú ÀÓÇöõÆ®, ¿þ¾î·¯ºí ½Å°æ Àڱرâ, ºñħ½ÀÀû ³úÆÄ ±â¹Ý ½Ã½ºÅÛÀº °³ÀÎÀÇ ¿îµ¿ ´É·Â ȸº¹, ÀÇÁ· Á¦¾î, ½Å°æ ½ÅÈ£¸¦ ÀÌ¿ëÇÑ ÀÇ»ç¼ÒÅëÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ´º·ÎÅ×Å©´Â Á¤½Å°Ç°­ Ä¡·á¿¡¼­µµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, °æµÎ°³ÀÚ±âÀÚ±Ø(TMS)°ú ¹ÌÁֽŰæÀÚ±Ø(VNS)Àº Ä¡·á ÀúÇ×¼º ¿ì¿ïÁõ°ú ºÒ¾ÈÀå¾Ö¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¹ýÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. ÀÎÁö ÈÆ·Ã, ÁýÁß·Â Çâ»ó, ½ºÆ®·¹½º °ü¸®¸¦ À§ÇÑ ´º·ÎÇǵå¹é ±â±âÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ¾î ´º·ÎÅ×Å©ÀÇ Àü¸ÁÀº ´õ¿í ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×ÀÇ ¹ßÀüÀ¸·Î ½Ç½Ã°£ ½Å°æ µ¥ÀÌÅÍ ºÐ¼®ÀÌ °¡´ÉÇØÁö¸é¼­ Á¤¹Ð ½Å°æÄ¡·áÀÇ ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿Í ½Å°æ ÅðÇ༺ ÁúȯÀÇ À¯Çà¿¡ µû¶ó ´º·Î Å×Å© ÀåÄ¡´Â ÁÖ·ù ÀÇ·á¿¡ Á¡Á¡ ´õ ¸¹ÀÌ ÅëÇÕµÇ¾î ½Å°æ ÀçȰÀ» °­È­ÇÏ°í ³ú¿Í ±â°èÀÇ Á÷Á¢ÀûÀÎ »óÈ£ ÀÛ¿ëÀ» ÅëÇØ Àΰ£ÀÇ ÀáÀç·ÂÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù.

´º·ÎÅ×Å© µð¹ÙÀ̽ºÀÇ º¸±ÞÀ» °¡·Î¸·°í ÀÖ´Â °úÁ¦´Â ¹«¾ùÀΰ¡?

±Þ¼ÓÇÑ ¹ßÀü¿¡µµ ºÒ±¸Çϰí, ´º·ÎÅ×Å© ÀåÄ¡´Â º¸±ÞÀ» ¹æÇØÇÏ´Â ¸î °¡Áö µµÀü¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÁÖ¿ä Àå¾Ö¹° Áß Çϳª´Â ƯÈ÷ À̽ÄÇü BCI¿Í °í±Þ ½Å°æÁ¶Àý Ä¡·áÀÇ °³¹ß ¹× µµÀÔ ºñ¿ëÀÌ ³ô´Ù´Â Á¡ÀÔ´Ï´Ù. ³ú-ÄÄÇ»ÅÍ ÀÎÅÍÆäÀ̽º¿Í ½Å°æ ÀÚ±Ø ±â¼úÀ» µÑ·¯½Ñ À±¸®Àû, ±ÔÁ¦Àû ¿ì·Á´Â Àå±âÀûÀÎ ¾ÈÀü¼º, ÇÁ¶óÀ̹ö½Ã, ½Å°æ µ¥ÀÌÅÍ ¾Ç¿ë °¡´É¼º µî ¿©ÀüÈ÷ ½Ã±ÞÇÑ ¹®Á¦À̱⠶§¹®¿¡ Ãß°¡ÀûÀÎ Àå¾Ö¹°ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ³ú ½ÅÈ£ ÇØ¼®ÀÇ º¹À⼺°ú ȯÀÚ ¹ÝÀÀÀÇ ÆíÂ÷µµ ½Å°æ±â¼ú Àû¿ëÀÇ ½Å·Ú¼º°ú À¯È¿¼º¿¡ µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¸¹Àº ´º·ÎÅ×Å© µð¹ÙÀ̽º´Â Å« ¿¬»ê ´É·Â°ú ½Ç½Ã°£ ó¸® ´É·ÂÀ» ÇÊ¿ä·Î Çϸç, ÀÌ´Â ¿¡³ÊÁö ¼Òºñ¿Í µð¹ÙÀ̽ºÀÇ ¼ÒÇüÈ­¿¡ ´ëÇÑ ¿ì·Á·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ħ½ÀÀûÀÎ ³ú ÀÓÇöõÆ®¿¡ ´ëÇÑ È¸ÀÇÀûÀÎ ½Ã°¢°ú Ä¿³ØÆ¼µå ´º·ÎÅ×Å© ¼Ö·ç¼ÇÀÇ µ¥ÀÌÅÍ º¸¾È¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ µµÀÔÀÌ ´õµð°Ô ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ´º·ÎÅ×Å© Ç÷§Æû °£ÀÇ Ç¥ÁØÈ­ ¹× ±âÁ¸ ÇコÄÉ¾î ½Ã½ºÅÛ°úÀÇ »óÈ£¿î¿ë¼º¿¡´Â ¾ÆÁ÷ ÇØ°áµÇÁö ¾ÊÀº ¹®Á¦°¡ ³²¾ÆÀÖ¾î ÀÓ»ó ¿öÅ©Ç÷ο쿡 ÅëÇÕÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§Çؼ­´Â ½Å°æÀ±¸®Çп¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í, ½Å°æ°úÇÐÀÚ¿Í ¿£Áö´Ï¾îÀÇ ´ÙÇÐÁ¦Àû Çù·Â üÁ¦¸¦ ±¸ÃàÇϸç, »ç¿ëÀÚÀÇ Á¢±Ù¼º°ú ¾ÈÀü¼ºÀ» Çâ»ó½ÃŰ´Â ÀúÀü·Â ¹«¼± ´º·ÎÅ×Å© ¼Ö·ç¼Ç °³¹ßÀ» ÃßÁøÇØ¾ß ÇÕ´Ï´Ù.

´º·ÎÅ×Å©ÀÇ ÇѰ踦 ¶Ù¾î³Ñ´Â Çõ½ÅÀ̶õ?

´º·ÎÅ×Å© ½ÃÀåÀº ±Þ¼ÓÇÑ ±â¼ú Çõ½ÅÀÌ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, »õ·Î¿î ±â¼ú·Î ÀÎÇØ ³ú-±â°è ÀÎÅÍÆäÀ̽º¿Í ½Å°æÁ¶Àý ÀåÄ¡ÀÇ ±â´É, Á¤È®¼º, Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. °í¹ÐµµÀÇ À¯¿¬ÇÑ ½Å°æ ÀÓÇöõÆ®ÀÇ °³¹ß·Î ³ú ½ÅÈ£ÀÇ È¹µæÀÌ Çâ»óµÇ°í, ÀåÄ¡ÀÇ ¼º´ÉÀÌ ¿À·¡ Áö¼ÓµÉ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. AI°¡ žÀçµÈ BCI´Â ½Å°æ Ȱµ¿À» º¸´Ù ºü¸£°í Á¤È®ÇÏ°Ô ÇØµ¶ÇÒ ¼ö ÀÖ°Ô ÇØÁÖ°í, »ý°¢À» Á÷Á¢ Á¦¾îÇÒ ¼ö ÀÖ´Â ÀåÄ¡ÀÇ ¹®À» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ±â´É¼º ±ÙÀû¿Ü¼± ºÐ±¤¹ý(fNIRS), °Ç½Ä Àü±Ø EEG Çìµå¼Â µî ºñħ½ÀÀû ½Å°æ±â¼ú ¼Ö·ç¼ÇÀÇ µîÀåÀ¸·Î ½Å°æ±â¼úÀº °ÔÀÓ, »ý»ê¼º Çâ»ó, ¸í»ó µî ´Ù¾çÇÑ ¼ÒºñÀÚ¿ë ¾ÖÇø®ÄÉÀ̼ǿ¡ ´õ¿í ½±°Ô Ȱ¿ëµÉ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ½Å°æ Àڱصµ ÁøÈ­Çϰí ÀÖÀ¸¸ç, ½Ç½Ã°£ ³ú Ȱµ¿À» ±â¹ÝÀ¸·Î ÀÚ±Ø ÆÄ¶ó¹ÌÅ͸¦ ÀÚµ¿À¸·Î Á¶Á¤ÇÏ´Â Æó¼â ·çÇÁ Çǵå¹é ½Ã½ºÅÛÀ» ÅëÇØ °£Áú, ¸¸¼º ÅëÁõ µîÀÇ Áõ»ó¿¡ ´ëÇÑ È¿°ú°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¹«¼± ½Å°æ±â¼úÀÇ ¹ßÀüÀ¸·Î ³ú ¼¾¼­¿Í ¿ÜºÎ ±â±âÀÇ ¿øÈ°ÇÑ ¿¬°áÀÌ °¡´ÉÇØÁö¸é¼­ ħ½ÀÀû ½Ã¼úÀÇ Çʿ伺ÀÌ ÁÙ¾îµé°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´º·ÎÅ×Å©¿Í Áõ°­Çö½Ç(AR), °¡»óÇö½Ç(VR)ÀÇ À¶ÇÕÀ¸·Î ÀÎÁöÄ¡·á, ÅëÁõ°ü¸®, ½Å°æÀçȰ¿¡ »õ·Î¿î °¡´É¼ºÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀÌ °¡¼ÓÈ­µÊ¿¡ µû¶ó ´º·ÎÅ×Å©´Â ´õ¿í Á¤±³ÇØÁö°í, °³ÀÎÈ­µÇ°í, ÀÏ»ó »ýȰ¿¡ ÅëÇյǾî Àΰ£°ú ÄÄÇ»ÅÍÀÇ »óÈ£ ÀÛ¿ëÀÇ ¹Ì·¡¸¦ º¯È­½Ã۰í ÀÖ½À´Ï´Ù.

´º·ÎÅ×Å© µð¹ÙÀ̽º ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

´º·ÎÅ×Å© µð¹ÙÀ̽º ½ÃÀåÀÇ ¼ºÀåÀº ½Å°æÁúȯ À¯º´·ü Áõ°¡, ³ú-±â°è ÀÎÅÍÆäÀ̽º ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ÀÎÁö±â´É Çâ»ó ±â¼ú¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ °ü½É Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °£Áú, ¿ì¿ïÁõ, ÆÄŲ½¼º´ µîÀÇ Áúȯ¿¡ ´ëÇÑ ºñħ½ÀÀû À̽ÄÇü µð¹ÙÀ̽º°¡ FDAÀÇ ½ÂÀÎÀ» ¹ÞÀ¸¸é¼­ ½Å°æÀÚ±ØÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. AI ±â¹Ý ³ú-ÄÄÇ»ÅÍ ÀÎÅÍÆäÀ̽ºÀÇ È®ÀåÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖÀ¸¸ç, °¢ ±â¾÷Àº ¸¶Àεå ÄÁÆ®·Ñ ÀÇÁ·, º¸Á¶ Ä¿¹Â´ÏÄÉÀÌ¼Ç µµ±¸, ÇÚÁîÇÁ¸® ÄÄÇ»ÆÃ ¼Ö·ç¼Ç µîÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¼ö¸é °³¼± ¹× ½ºÆ®·¹½º ¿ÏÈ­¸¦ À§ÇÑ ´º·ÎÇǵå¹é ±â±â µî À£´Ï½º ¹× Á¤½Å°Ç°­ ºÐ¾ß¿¡¼­ ¿þ¾î·¯ºí ´º·ÎÅ×Å©ÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÓ»óÀû ¿ëµµ ¿Ü¿¡µµ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í ½Ç½Ã°£ ³ú ¸ð´ÏÅ͸µÀÇ ÃßÁøÀº Â÷¼¼´ë ³úÆÄ ¹× ½Å°æ ¿µ»ó ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇÏ¿© ½Å°æÇÐÀû Áø´ÜÀÇ Á¤È®¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ ºê·¹ÀÎ ÀÌ´Ï¼ÅÆ¼ºê(BRAIN Initiative), À¯·´ ÈÞ¸Õ ºê·¹ÀÎ ÇÁ·ÎÁ§Æ®(European Human Brain Project) µî ½Å°æ±â¼ú ¿¬±¸¸¦ Áö¿øÇÏ´Â Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê°¡ ±â¼ú Çõ½Å°ú »ó¿ëÈ­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ´º·ÎÅ×Å© µð¹ÙÀ̽º°¡ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ±× ¿ëµµ´Â ÇコÄɾî, ¼ÒºñÀÚ ±â¼ú, ±¹¹æ, Àΰ£ È®ÀåÀ¸·Î È®´ëµÉ °ÍÀ̸ç, ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀåÀÌ ±Þ¼ºÀåÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(½Å°æ ÀÚ±Ø, ½Å°æ Àΰø±â°ü, ´º·Î ¼¾½Ì, ½Å°æ ÀçȰ), º´Å À¯Çü(ÆÄŲ½¼º´, ÅëÁõ °ü¸®, ÀÎÁöÀå¾Ö, °£Áú, ¿ä½Ç±Ý¡¤º¯½Ç±Ý, û°¢Àå¾Ö, ¿ì¿ïÁõ, ¼ö¸éÀå¾Ö)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡°¡ ¼±º°ÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Neurotech Devices Market to Reach US$30.3 Billion by 2030

The global market for Neurotech Devices estimated at US$15.2 Billion in the year 2024, is expected to reach US$30.3 Billion by 2030, growing at a CAGR of 12.2% over the analysis period 2024-2030. Neurostimulation, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$12.4 Billion by the end of the analysis period. Growth in the Neuroprostheses segment is estimated at 14.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.1 Billion While China is Forecast to Grow at 16.1% CAGR

The Neurotech Devices market in the U.S. is estimated at US$4.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.3 Billion by the year 2030 trailing a CAGR of 16.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 10.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.

Global Neurotech Devices Market - Key Trends & Drivers Summarized

How Are Neurotech Devices Revolutionizing Brain-Computer Interaction and Neural Health?

Neurotech devices are transforming the way humans interact with technology, enabling brain-computer interfaces (BCIs), neurostimulation therapies, cognitive enhancement, and real-time neurological monitoring. These devices bridge the gap between neuroscience and digital technology, offering groundbreaking solutions for conditions such as epilepsy, depression, Parkinson’s disease, and spinal cord injuries. Brain implants, wearable neurostimulation devices, and non-invasive EEG-based systems are enabling individuals to regain mobility, control prosthetics, and communicate using neural signals. Neurotech is also playing a crucial role in mental health treatment, with transcranial magnetic stimulation (TMS) and vagus nerve stimulation (VNS) emerging as effective therapies for treatment-resistant depression and anxiety disorders. The growing adoption of neurofeedback devices for cognitive training, focus improvement, and stress management is further expanding the neurotech landscape. Advances in artificial intelligence (AI) and machine learning are enabling real-time neural data analysis, paving the way for precision neurotherapies. As the global population ages and neurodegenerative disorders become more prevalent, neurotech devices are increasingly being integrated into mainstream healthcare, enhancing neurological rehabilitation and expanding human potential through direct brain-machine interaction.

What Challenges Are Slowing the Adoption of Neurotech Devices?

Despite rapid advancements, neurotech devices face several challenges that hinder widespread adoption. One of the key obstacles is the high cost of development and implementation, particularly for implantable BCIs and advanced neuromodulation therapies. Ethical and regulatory concerns surrounding brain-computer interfaces and neurostimulation technologies pose additional hurdles, as long-term safety, privacy, and potential misuse of neurodata remain pressing concerns. The complexity of brain signal interpretation and variability in patient responses also challenge the reliability and effectiveness of neurotech applications. Many neurotech devices require significant computational power and real-time processing capabilities, leading to concerns about energy consumption and device miniaturization. Additionally, public skepticism regarding invasive brain implants and concerns over data security in connected neurotech solutions slow adoption rates. Standardization across different neurotech platforms and interoperability with existing healthcare systems remain unresolved issues, making integration into clinical workflows more difficult. Addressing these challenges requires increased investment in neuroethics, cross-disciplinary collaboration between neuroscientists and engineers, and advancements in low-power, wireless neurotech solutions that improve user accessibility and safety.

How Are Innovations Pushing the Boundaries of Neurotech?

The neurotech market is undergoing rapid innovation, with new technologies enhancing the functionality, accuracy, and accessibility of brain-machine interfaces and neuromodulation devices. The development of high-density, flexible neural implants is allowing for improved brain signal acquisition and longer-lasting device performance. AI-powered BCIs are enabling faster and more accurate decoding of neural activity, opening doors for direct thought-controlled devices. The rise of non-invasive neurotech solutions, such as functional near-infrared spectroscopy (fNIRS) and dry-electrode EEG headsets, is making neurotechnology more accessible for consumer applications, including gaming, productivity enhancement, and meditation. Neurostimulation is also evolving, with closed-loop feedback systems that automatically adjust stimulation parameters based on real-time brain activity, improving efficacy for conditions such as epilepsy and chronic pain. Advances in wireless neurotech are enabling seamless connectivity between brain sensors and external devices, reducing the need for invasive procedures. Additionally, the convergence of neurotech with augmented reality (AR) and virtual reality (VR) is opening new possibilities in cognitive therapy, pain management, and neurorehabilitation. As innovation accelerates, neurotech is becoming more sophisticated, personalized, and integrated into everyday life, transforming the future of human-computer interaction.

What Is Driving the Growth of the Neurotech Devices Market?

The growth in the neurotech devices market is driven by several factors, including the increasing prevalence of neurological disorders, rising investments in brain-machine interface research, and growing consumer interest in cognitive enhancement technologies. The demand for neurostimulation therapies is surging as non-invasive and implantable devices gain FDA approvals for conditions such as epilepsy, depression, and Parkinson’s disease. The expansion of AI-driven brain-computer interfaces is further fueling market growth, with companies developing mind-controlled prosthetics, assistive communication tools, and hands-free computing solutions. The growing adoption of wearable neurotech in wellness and mental health, including neurofeedback devices for sleep improvement and stress reduction, is expanding the market beyond clinical applications. The push for personalized medicine and real-time brain monitoring is driving investment in next-generation EEG and neuroimaging technologies, enhancing the precision of neurological diagnostics. Additionally, government initiatives supporting neurotechnology research, such as the U.S. BRAIN Initiative and the European Human Brain Project, are fostering innovation and commercialization. As neurotech devices continue to evolve, their applications are expanding across healthcare, consumer technology, defense, and human augmentation, positioning the market for rapid growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Neurotech Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Neurostimulation, Neuroprostheses, Neurosensing, Neurorehabilitation); Condition Type (Parkinson's Disease, Pain Management, Cognitive Disorders, Epilepsy, Urinary & Fecal Incontinence, Hearing Conditions, Depression, Sleep Disorders)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â